The clinical symptoms of Alzheimer’s disease (AD) are preceded by a long asymptomatic period associated with “silent” deposition of aberrant paired helical filament (PHF)-tau and amyloid-beta proteins in brain tissue. Similar depositions have been reported within the olfactory epithelium (OE), a tissue that can be biopsied in vivo. The degree to which such biopsies are useful in identifying AD is controversial. This postmortem study had 3 main goals: first, to quantify the relative densities of AD-related proteins in 3 regions of the olfactory neuroepithelium, namely, the nasal septum, middle turbinate, and superior turbinate; second, to establish whether such densities are correlated among these epithelial regions as well as with semi-quantitative ratings of general brain cortex pathology; and third, to evaluate correlations between the protein densities and measures of antemortem cognitive function.
Methods:
Postmortem blocks of olfactory mucosa were obtained from 12 AD cadavers and 24 controls and subjected to amyloid-beta and PHF-tau immunohistochemistry.
Results:
We observed marked heterogeneity in the presence of the biomarkers of tau and amyloid-beta among the targeted olfactory epithelial regions. No significant difference was observed between the cadavers with AD and the controls regarding the concentration of these proteins in any of these epithelial regions. Only one correlation significant was evident, namely, that between the tau protein densities of the middle and the upper turbinate (r = .58, P = .002).
Conclusion:
AD-related biomarker heterogeneity, which has not been previously demonstrated, makes comparisons across studies difficult and throws into question the usefulness of OE amyloid-beta and PHF-tau biopsies in detecting AD.
GoedertM.Neurodegeneration. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. Science. 2015;349(6248):1255555.
2.
KanekiyoTCirritoJRLiuC-Cet al. Neuronal clearance of amyloid-β by endocytic receptor LRP1. J Neurosci. 2013;33(49):19276-19283.
3.
LiSDengJHouHet al. Specific antibody binding to the APP672-699 region shifts APP processing from α- to β-cleavage. Cell Death Dis. 2014;5:e1374.
4.
BlennowK.CSF biomarkers for mild cognitive impairment. J Intern Med. 2004;256(3):224-234.
5.
DotyRLHawkesCHGoodKPDudaJE. Odor perception and neuropathology in neurodegenerative diseases and schizophrenia. In: DotyRL, ed. Handbook of Olfaction and Gustation. New Jersey: John Wiley & Sons, Inc; 2015: 403-452.
6.
HumpelC.Identifying and validating biomarkers for Alzheimer’s disease. Trends Biotechnol. 2011;29(1):26-32.
7.
TalamoBRRudelRKosikKSet al. Pathological changes in olfactory neurons in patients with Alzheimer’s disease. Nature. 1989;337(6209):736-739.
8.
ArnoldSELeeEBMobergPJet al. Olfactory epithelium amyloid-β and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol. 2010;67(4):462-469.
9.
FujishiroHTsuboiYLinW-LUchikadoHDicksonDW.Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer’s disease with amygdala Lewy bodies. Acta Neuropathol. 2008;116(1):17-24.
10.
HongSMParkIHKimKMShinJMLeeHM.Relationship between the Korean version of the sniffin’ stick test and the TandT olfactometer in the Korean population. Clin Exp Otorhinolaryngol. 2011;4(4):184-187.
11.
LeeJHGoedertMHillWDLeeVMTrojanowskiJQ.Tau proteins are abnormally expressed in olfactory epithelium of Alzheimer patients and developmentally regulated in human fetal spinal cord. Exp Neurol. 1993;121(1):93-105.
12.
PerryGCastellaniRJSmithMAet al. Oxidative damage in the olfactory system in Alzheimer’s disease. Acta Neuropathol. 2003;106(6):552-556.
13.
TabatonMCammarataSMancardiGLCordoneGPerryGLoebC.Abnormal tau-reactive filaments in olfactory mucosa in biopsy specimens of patients with probable Alzheimer’s disease. Neurology. 1991;41(3):391-394.
14.
YamagishiMIshizukaYSekiK.Pathology of olfactory mucosa in patients with Alzheimer’s disease. Ann Otol Rhinol Laryngol. 1994;103(6):421-427.
15.
ArnoldSESmutzerGSTrojanowskiJQMobergPJ.Cellular and molecular neuropathology of the olfactory epithelium and central olfactory pathways in Alzheimer’s disease and schizophrenia. Ann N Y Acad Sci. 1998;855:762-775.
16.
HockCGolombowskiSMuller-SpahnFet al. Histological markers in nasal mucosa of patients with Alzheimer’s disease. Eur Neurol. 1998;40(1):31-36.
17.
KaakkolaSPaloJMalmbergHSulkavaRVirtanenI.Neurofilament profile in olfactory mucosa of patients with a clinical diagnosis of Alzheimer’s disease. Virchows Arch. 1994;424(3):315-319.
18.
TrojanowskiJQNewmanPDHillWDLeeVM.Human olfactory epithelium in normal aging, Alzheimer’s disease, and other neurodegenerative disorders. J Comp Neurol. 1991;310(3):365-376.
19.
ArnoldSTrojanowskiJDotyRSmutzerG. Olfactory system neuropathology in Alzheimer’s disease, Parkinson’s disease, and schizophrenia. In: DotyRL, ed. Handbook of Olfaction and Gustation. New York: Marcel Dekker; 2003: 503-524.
20.
GrinbergLTLucena FerrettiREFarfelJMet al. Brain bank of the Brazilian aging brain study group—a milestone reached and more than 1,600 collected brains. Cell Tissue Bank. 2007;8(2):151-162.
21.
JormAFJacombPA.The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med. 1989;19(4):1015-1022.
22.
MorrisJC.The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
23.
FerrettiRDaminABruckiSMorilloLPerrocoTCamporaF.Post-mortem diagnosis of dementia by informant interview. Dement Neuropsychol. 2010;4(2):138-144.
24.
SuemotoCKNitriniRGrinbergLTet al. Atherosclerosis and dementia: a cross-sectional study with pathological analysis of the carotid arteries. Stroke. 2011;42(12):3614=3615.
25.
FarfelJMNitriniRSuemotoCKet al. Very low levels of education and cognitive reserve: a clinicopathologic study. Neurology. 2013;81(7):650-657.
26.
MirraSHeymanAMcKeelDSumiS. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;46(1):142-145.
27.
BraakHBraakE.Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
28.
Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging. 1997;18(4Suppl):S1-2.
KernR.Chronic sinusitis and anosmia: pathologic changes in the olfactory mucosa. Laryngoscope. 2000;110(7):1071-1077.
31.
HolbrookEHWuECurryWTLinDTSchwobJE.Immunohistochemical characterization of human olfactory tissue. Laryngoscope. 2011;121(8):1687-1701.
32.
Calderon-GarciduenasLFranco-LiraMHenriquez-RoldanCet al. Urban air pollution: influences on olfactory function and pathology in exposed children and young adults. Exp Toxicol Pathol. 2010;62(1):91-102.
33.
DotyRLKamathV.The influences of age on olfaction: a review. Front Psychol. 2014;5:1-20.
34.
GuarnerosMHummelTMartinez-GomezMHudsonR.Mexico City air pollution adversely affects olfactory function and intranasal trigeminal sensitivity. Chem Senses. 2009;34(9):819-826.
35.
BlennowKHampelHWeinerMZetterbergH.Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144.
36.
BlennowK.CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn. 2005;5(5):661-672.
37.
GalaskoDHansenLAKatzmanRet al. Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch Neurol. 1994;51(9):888-895.
38.
JellingerKA.Diagnostic accuracy of Alzheimer’s disease: a clinicopathological study. Acta Neuropathol. 1996;91(2):219-220.
39.
LimATsuangDKukullWet al. Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc. 1999;47(5):564-569.
40.
MarksteinerJHinterhuberHHumpelC.Cerebrospinal fluid biomarkers for diagnosis of Alzheimer’s disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. Drugs Today (Barc). 2007; 43(6):423-431.
41.
WhitwellJLJosephsKAMurrayMEet al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71(10):743-749.
42.
IkonomovicMDKlunkWEAbrahamsonEEet al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131(Pt 6):1630-1645.
43.
JobstKABarnetsonLPShepstoneBJ.Accurate prediction of histologically confirmed Alzheimer’s disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Me. Int Psychogeriatr. 1998;10(3):271-302.
44.
TapiolaTAlafuzoffIHerukkaS-Ket al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382-389.
45.
VelayudhanL.Smell identification function and Alzheimer’s disease: a selective review. Curr Opin Psychiatry. 2015; 28(2):173-179.
46.
GrowdonMESchultzAPDagleyASet al. Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology. 2015;84(21):2153-2160.
47.
Bahar-FuchsAChetelatGVillemagneVLet al. Olfactory deficits and amyloid-beta burden in Alzheimer’s disease, mild cognitive impairment, and healthy aging: a PiB PET study. J Alzheimers Dis. 2010;22(4):1081-1087.
48.
WilsonRSArnoldSESchneiderJATangYBennettDA.The relationship between cerebral Alzheimer’s disease pathology and odour identification in old age. J Neurol Neurosurg Psychiatry. 2007;78(1):30-35.
49.
DotyRL.Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate?Lancet Neurol. 2017;16(6):478-488.
50.
AttemsJJellingerKA.Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin Neuropathol. 2006;25(6):265-271.
51.
AttemsJWalkerLJellingerKA.Olfactory bulb involvement in neurogenerative diseases. Acta Neuropathol. 2014;127:459-75.
52.
CrinoPBMartinJAHillWDGreenbergBLeeVMTrojanowskiJQ.Beta-amyloid peptide and amyloid precursor proteins in olfactory mucosa of patients with Alzheimer’s disease, Parkinson’s disease, and Down syndrome. Ann Otol Rhinol Laryngol. 1995;104(8):655-661.
53.
MoonJLeeS-TKongIGet al. Early diagnosis of Alzheimer’s disease from elevated olfactory mucosal miR-206 level. Sci Rep. 2016;6:20364.
54.
WrobelBBMazzaJMEvgrafovO VKnowlesJA.Assessing the efficacy of endoscopic office olfactory biopsy sites to produce neural progenitor cell cultures for the study of neuropsychiatric disorders. Int Forum Allergy Rhinol. 2013;3(2):133-138.
55.
AndrewsPJPoirrierALLundVJChoiD.Safety of human olfactory mucosal biopsy for the purpose of olfactory ensheathing cell harvest and nerve repair: a prospective controlled study in patients undergoing endoscopic sinus surgery. Rhinology. 2016;54(2):183-191.
56.
HummelTWhitcroftKLAndrewsPet al. Position paper on olfactory dysfunction. Rhinol Suppl. 2017;54(26):1-30.
